Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Akeso
Pharma
Enhertu successor, ESMO, Gilead—Fierce Pharma Asia
Fierce provides a deep dive into the hunt for the next Enhertu in breast cancer. ESMO 2026 data featured Chinese assets backed by Big Pharma.
Angus Liu
Oct 30, 2026 8:45am
Akeso CEO looks for more ivonescimab combos after AZ deal
Oct 25, 2026 11:30am
US' China deal policy, WCLC, Legend CEO—Fierce Pharma Asia
Sep 18, 2026 10:20am
Ivonescimab tops Keytruda with strong OS in PD-L1-high NSCLC
Sep 13, 2026 8:00am
Roche, GSK, Novartis, MFN, Akeso and more—Fierce Pharma Asia
Sep 4, 2026 8:52am
Akeso, Summit’s ivonescimab hits OS goal in Keytruda head-to-head
Sep 3, 2026 10:29am
